Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 20/20 | 0.75 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1427642 | 1.00 | GCK (0.75) | GCKKCNH2CYP1A2ABCB1CYP3A4 | |
| SCHEMBL2662756 | 0.92 | GCK (0.73) | GCKKCNH2CYP1A2ABCB1CYP3A4 | |
| SCHEMBL1426943 | 0.92 | GCK (0.73) | GCKKCNH2CYP1A2ABCB1CYP3A4 | |
| SCHEMBL2667114 | 0.92 | GCK (0.63) | GCKKCNH2CYP1A2ABCB1CYP3A4 | |
| SCHEMBL1140709 | 0.92 | GCK (0.73) | GCKKCNH2CYP1A2ABCB1CYP3A4 | |
| SCHEMBL320649 | 0.92 | GCK (0.73) | GCKKCNH2CYP1A2ABCB1CYP3A4 | |
| SCHEMBL1427151 | 0.91 | GCK (0.64) | GCKKCNH2CYP1A2ABCB1CYP3A4 | |
| SCHEMBL12742046 | 0.91 | GCK (0.72) | GCKKCNH2CYP1A2ABCB1CYP3A4 | |
| SCHEMBL12782092 | 0.91 | GCK (0.72) | GCKKCNH2CYP1A2ABCB1CYP3A4 | |
| SCHEMBL1107651 | 0.89 | GCK (0.68) | GCKKCNH2CYP1A2ABCB1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012007758-A2 | PHARMACEUTICAL FORMULATIONS | ASTRAZENECA AB (SE) | 2012-01-19 | — | — | WO | disclosed |
| WO-2012007758-A2 | PHARMACEUTICAL FORMULATIONS | ASTRAZENECA AB (SE) | 2012-01-19 | — | — | WO | disclosed |
| US-8093252-B2 | Crystalline polymorphic form of glucokinase activator | ASTRAZENECA AB (SE) | 2012-01-10 | — | — | US | disclosed |
| US-8093252-B2 | Crystalline polymorphic form of glucokinase activator | ASTRAZENECA AB (SE) | 2012-01-10 | — | — | US | disclosed |
| US-8093252-B2 | Crystalline polymorphic form of glucokinase activator | ASTRAZENECA AB (SE) | 2012-01-10 | — | — | US | disclosed |
| US-8076481-B2 | Chemical process 632 | ASTRAZENECA AB (SE) | 2011-12-13 | — | — | US | disclosed |
| US-8076481-B2 | Chemical process 632 | ASTRAZENECA AB (SE) | 2011-12-13 | — | — | US | disclosed |
| US-8076481-B2 | Chemical process 632 | ASTRAZENECA AB (SE) | 2011-12-13 | — | — | US | disclosed |
| US-20100210621-A1 | CRYSTALLINE POLYMORPHIC FORM 631 | ASTRAZENECA AB (SE) | 2010-08-19 | — | — | US | disclosed |
| US-20100210621-A1 | CRYSTALLINE POLYMORPHIC FORM 631 | ASTRAZENECA AB (SE) | 2010-08-19 | — | — | US | disclosed |
| US-20100210621-A1 | CRYSTALLINE POLYMORPHIC FORM 631 | ASTRAZENECA AB (SE) | 2010-08-19 | — | — | US | disclosed |
| US-20100210841-A1 | CHEMICAL PROCESS 632 | ASTRAZENECA AB (SE) | 2010-08-19 | — | — | US | disclosed |
| US-20100210841-A1 | CHEMICAL PROCESS 632 | ASTRAZENECA AB (SE) | 2010-08-19 | — | — | US | disclosed |
| US-20100210841-A1 | CHEMICAL PROCESS 632 | ASTRAZENECA AB (SE) | 2010-08-19 | — | — | US | disclosed |
| WO-2010092386-A1 | CRYSTALLINE POLYMORPHIC FORM 631 | ASTRAZENECA AB (SE) | 2010-08-19 | — | — | WO | disclosed |
| WO-2010092387-A1 | PROCESS FOR PREPARATION OF BEZOYL AMINO HETEROCYCLYL COMPOUNDS | ASTRAZENECA AB (SE) | 2010-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210841-A1 | CHEMICAL PROCESS 632 | F12, XDH, REN | GCK 2360/4885KCNH2 837/4885CYP1A2 14/4885 |
| US-20100210621-A1 | CRYSTALLINE POLYMORPHIC FORM 631 | GCKR, GCK, HK1 | GCK 2/4885KCNH2 631/4885CYP1A2 1358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.